Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis.

Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis.

<h4>Background</h4>A nonavalent human papillomavirus (HPV) vaccine has been licensed for use in women and men up to age 45 years in the United States. The cost-effectiveness of HPV vaccination for women and men aged 30 to 45 years in the context of cervical cancer screening practice was...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jane J Kim, Kate T Simms, James Killen, Megan A Smith, Emily A Burger, Stephen Sy, Catherine Regan, Karen Canfell
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
Medicine
R
Acceso en línea:https://doaj.org/article/c7a9a728c2a34564b00d467c9944ca6f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares